hVIVO achieves exceptional financial performance, marked by record revenues

hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its audited results for the year ended 31 December 2023.

Financial highlights

Revenue up 16% to £56.0 million (2022: £48.5 million)
EBITDA up 44% to £13.0 million (2022: £9.1 million)
EBITDA margins of 23.3% (2022: 18.7%)
Cash and cash equivalents of £37.0 million as at 31 December 2023 (31 December 2022: £28.4 million)
Adjusted basic EPS increased 32% to 1.27p per share (2022: 0.96p)
Weighted contracted orderbook of £80 million as at 31 December 2023 (31 December 2022: £76 million)
Dividend for the year of c.£1.4 million (0.20p per Ordinary Share) as the Company commences an annual dividend policy
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO 2024 Year in Review

    Discover how hVIVO Group’s innovative approach to human challenge trials and infectious disease expertise has shaped the future of pharmaceutical research in 2024.

    hVIVO plc

    Blood biomarkers for viral infection diagnosis and management

    Host response biomarkers to viral infections have significant potential in clinical applications, such as guiding diagnostic decisions, reducing unnecessary antibiotic use, and triggering infection control protocols or antiviral treatments. Research on these biomarkers has largely focused